GlassScriptPhysician profile
John H Kendrick
NPI 1902812019
$1,512.05
in general payments reported to CMS, 2019-2025
28 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.01 · 2020: $54.71 · 2021: $316 · 2022: $309 · 2023: $210 · 2024: $445 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $285.49 | 2022-2025 | Via Matrix, Puraply, Affinity |
| Astrazeneca Pharmaceuticals LP | $238.47 | 2020-2024 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $195.34 | 2021-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $79.53 | 2021-2022 | |
| Abbvie INC. | $70.60 | 2021-2022 | |
| Eisai INC. | $68.61 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.51 | 2023 | Belsomra |
| Pfizer INC. | $43.81 | 2020-2024 | |
| Collegium Pharmaceutical, INC. | $40.68 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $38.45 | 2022-2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $37.02 | 2024 | Voquezna |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Lilly USA, LLC | $32.63 | 2023-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $31.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.53 | 2022-2023 | Gattex |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $28.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.95 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $23.57 | 2024 | |
| Biogen, INC. | $18.13 | 2024 | Skyclarys |
| Dexcom, INC. | $17.98 | 2025 | Dexcom G6 Transmitter |
| Zimmer Biomet Holdings, INC. | $17.16 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Phadia US INC. | $17.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.83 | 2021 | |
| Indivior INC. | $15.20 | 2020 | |
| Biocompatibles, INC. | $14.94 | 2019 | |
| Bioventus LLC | $14.93 | 2024 | Durolane |
| Vertex Pharmaceuticals Incorporated | $14.56 | 2024 | |
| Abbott Laboratories | $13.30 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.